Basic studies for the development of a PET cancer imaging agent utilizing physical and biological properties of Zn-63

利用Zn-63的物理和生物学特性开发PET癌症显像剂的基础研究

• 批准号: 20591488
• 负责人: FURUKAWA Takako
• 金额: $ 2.58万
• 依托单位: National Institute of Radiological Sciences
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20591488/
• 关键词: 腫瘍; PET; Zn-63; 亜鉛; イメージング; Zn-EDDA; 種瘍

Zinc-63 is a positron emitter with 38 min half life and can be produced with a small clinical cyclotron targeting Cu-63, the most abundant Cu isotope, which makes Zn-63 attractive for clinical use. Zn is necessary for cell proliferation and supposed to be involved in cancer development. In this study, we explored the possibility to use Zn-63 for cancer imaging. We found that the uptake of Zn by cancer cells was found to be correlated with Zn content, suggesting that the uptake reflects the physiological needs of the cells, and that EDDA, a relatively weak chelator of Zn, worked favorably for caner imaging. We also found that adjusting the dose, higher accumulation of Zn into tumor mass was achievable. The small animal PET imaging of tumor in mouse model was successful with Zn-63 produced in our institute.

Zinc-63 是一种半衰期为 38 分钟的正电子发射体，可以通过针对 Cu-63（最丰富的 Cu 同位素）的小型临床回旋加速器来生产，这使得 Zn-63 对临床应用具有吸引力。锌是细胞增殖所必需的，并且被认为与癌症的发展有关。在这项研究中，我们探索了使用 Zn-63 进行癌症成像的可能性。我们发现癌细胞对锌的摄取与锌含量相关，这表明摄取反映了细胞的生理需求，而EDDA是一种相对较弱的锌螯合剂，有利于癌症成像。我们还发现，调整剂量，可以实现肿瘤块中锌的更高积累。利用我所生产的Zn-63对小鼠模型小动物肿瘤进行PET成像获得成功。

项目成果

Basic Evaluation of Zn-EDDA for Cancer Imaging

Zn-EDDA 用于癌症成像的基本评价

• 发表时间: 2009
• 作者: 古川高子;齋藤有里子;長谷川純崇;佐賀恒夫;藤林靖久
• 通讯作者: 藤林靖久

Zn-EDDAのPET腫瘍診断薬としての可能性を探る

探索 Zn-EDDA 作为 PET 肿瘤诊断剂的潜力

• 发表时间: 2008
• 作者: 古川高子;長谷川純崇;越川道子;須尭綾;齋藤有里子;曽川千鶴;佐賀恒夫;藤林靖久
• 通讯作者: 藤林靖久